Aigen Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-5,948
| Closed | -$685K | – | 911 |
|
|
2024
Q3 | $685K | Buy |
+5,948
| New | +$685K | 0.13% | 224 |
|
|
2024
Q2 | – | Sell |
-4,801
| Closed | -$662K | – | 936 |
|
|
2024
Q1 | $662K | Buy |
+4,801
| New | +$662K | 0.14% | 220 |
|
|
2022
Q4 | – | Sell |
-25,157
| Closed | -$2.67M | – | 692 |
|
|
2022
Q3 | $2.67M | Buy |
+25,157
| New | +$2.67M | 0.38% | 72 |
|
|
2022
Q1 | – | Sell |
-2,837
| Closed | -$233K | – | 892 |
|
|
2021
Q4 | $233K | Buy |
+2,837
| New | +$233K | 0.01% | 884 |
|
|
2021
Q3 | – | Sell |
-7,806
| Closed | -$760K | – | 596 |
|
|
2021
Q2 | $760K | Buy |
7,806
+2,378
| +44% | +$232K | 0.13% | 173 |
|
|
2021
Q1 | $528K | Buy |
+5,428
| New | +$528K | 0.07% | 283 |
|
|
2020
Q4 | – | Sell |
-6,937
| Closed | -$667K | – | 948 |
|
|
2020
Q3 | $667K | Buy |
6,937
+3,362
| +94% | +$323K | 0.09% | 345 |
|
|
2020
Q2 | $436K | Sell |
3,575
-4,349
| -55% | -$530K | 0.06% | 506 |
|
|
2020
Q1 | $686K | Sell |
7,924
-1,374
| -15% | -$119K | 0.09% | 325 |
|
|
2019
Q4 | $999K | Buy |
+9,298
| New | +$999K | 0.17% | 181 |
|